Empagliflozin as treatment in glycogen storage disease type IB patients
Background: Glycogen Storage Disease Ib (GSD Ib) is a disease that associates both neutropenia and neutrophil dysfunction, thereby causing recurrent infections and inflammatory bowel disease (IBD). As of now, the standard treatment of these complications has been the administration of granulocyte-st...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Molecular Genetics and Metabolism Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214426925000412 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849422451938689024 |
|---|---|
| author | María Arbelo Rodríguez Elena Márquez Mesa Cristina Lorenzo González Marina Gutiérrez Vilar Loredana Arhip Mónica Ruiz Pons José Pablo Suárez Llanos |
| author_facet | María Arbelo Rodríguez Elena Márquez Mesa Cristina Lorenzo González Marina Gutiérrez Vilar Loredana Arhip Mónica Ruiz Pons José Pablo Suárez Llanos |
| author_sort | María Arbelo Rodríguez |
| collection | DOAJ |
| description | Background: Glycogen Storage Disease Ib (GSD Ib) is a disease that associates both neutropenia and neutrophil dysfunction, thereby causing recurrent infections and inflammatory bowel disease (IBD). As of now, the standard treatment of these complications has been the administration of granulocyte-stimulating factor (GCSF). However, recent studies have found that the use of empagliflozin, an antidiabetic drug, may have benefits by reducing the levels of 1,5 anhydroglucitol-6-phosphate (1,5-AG6P), a metabolite that accumulates in the cytosol of neutrophils and blocks the use of glucose. Results: We therefore report our experience with three patients, one of them being a liver and kidney transplant recipient, with promising results. Morbidity has been greatly reduced in all cases consisting in weight gain, better neutrophil count and management of respiratory, osteoarticular and gastrointestinal comorbidities. Overall, an improvement in quality of life has been observed. Conclusion: SGLT2 inhibitors, and specifically empagliflozin offer promising results in improving morbidity and quality of life in patients with GSD Ib. In the cases presented, including a patient with double liver-kidney transplant, a good profile of tolerance, safety and effectiveness has been observed. Synopsis: Empagliflozin offers promising results in improving morbidity and quality of life in patients with GSD Ib, including the first double organ transplant patient treated with this drug. |
| format | Article |
| id | doaj-art-abf78d3be0ce417dbf3d005635ccc78c |
| institution | Kabale University |
| issn | 2214-4269 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Genetics and Metabolism Reports |
| spelling | doaj-art-abf78d3be0ce417dbf3d005635ccc78c2025-08-20T03:31:06ZengElsevierMolecular Genetics and Metabolism Reports2214-42692025-06-014310122610.1016/j.ymgmr.2025.101226Empagliflozin as treatment in glycogen storage disease type IB patientsMaría Arbelo Rodríguez0Elena Márquez Mesa1Cristina Lorenzo González2Marina Gutiérrez Vilar3Loredana Arhip4Mónica Ruiz Pons5José Pablo Suárez Llanos6Endocrinology and Nutrition Department, Hospital Universitario Nuestra Señora de Candelaria, Ctra. Del Rosario 145, Santa Cruz de Tenerife 38010, Spain; Corresponding author.Endocrinology and Nutrition Department, Hospital Universitario Nuestra Señora de Candelaria, Ctra. Del Rosario 145, Santa Cruz de Tenerife 38010, SpainEndocrinology and Nutrition Department, Hospital Universitario Nuestra Señora de Candelaria, Ctra. Del Rosario 145, Santa Cruz de Tenerife 38010, SpainPediatrics Department Hospital Universitario Nuestra Señora de Candelaria, Ctra. Del Rosario 145, Santa Cruz de Tenerife 38010, SpainNutricia-Danone, C/De Buenos Aires, 21, L'Eixample, Barcelona 08029, SpainPediatrics Department Hospital Universitario Nuestra Señora de Candelaria, Ctra. Del Rosario 145, Santa Cruz de Tenerife 38010, SpainEndocrinology and Nutrition Department, Hospital Universitario Nuestra Señora de Candelaria, Ctra. Del Rosario 145, Santa Cruz de Tenerife 38010, SpainBackground: Glycogen Storage Disease Ib (GSD Ib) is a disease that associates both neutropenia and neutrophil dysfunction, thereby causing recurrent infections and inflammatory bowel disease (IBD). As of now, the standard treatment of these complications has been the administration of granulocyte-stimulating factor (GCSF). However, recent studies have found that the use of empagliflozin, an antidiabetic drug, may have benefits by reducing the levels of 1,5 anhydroglucitol-6-phosphate (1,5-AG6P), a metabolite that accumulates in the cytosol of neutrophils and blocks the use of glucose. Results: We therefore report our experience with three patients, one of them being a liver and kidney transplant recipient, with promising results. Morbidity has been greatly reduced in all cases consisting in weight gain, better neutrophil count and management of respiratory, osteoarticular and gastrointestinal comorbidities. Overall, an improvement in quality of life has been observed. Conclusion: SGLT2 inhibitors, and specifically empagliflozin offer promising results in improving morbidity and quality of life in patients with GSD Ib. In the cases presented, including a patient with double liver-kidney transplant, a good profile of tolerance, safety and effectiveness has been observed. Synopsis: Empagliflozin offers promising results in improving morbidity and quality of life in patients with GSD Ib, including the first double organ transplant patient treated with this drug.http://www.sciencedirect.com/science/article/pii/S2214426925000412Glycogen storage disease type IbEmpagliflozinNeutropeniaNeutrophil dysfunctionSGLT2 inhibitors1,5-andhydroglucitol |
| spellingShingle | María Arbelo Rodríguez Elena Márquez Mesa Cristina Lorenzo González Marina Gutiérrez Vilar Loredana Arhip Mónica Ruiz Pons José Pablo Suárez Llanos Empagliflozin as treatment in glycogen storage disease type IB patients Molecular Genetics and Metabolism Reports Glycogen storage disease type Ib Empagliflozin Neutropenia Neutrophil dysfunction SGLT2 inhibitors 1,5-andhydroglucitol |
| title | Empagliflozin as treatment in glycogen storage disease type IB patients |
| title_full | Empagliflozin as treatment in glycogen storage disease type IB patients |
| title_fullStr | Empagliflozin as treatment in glycogen storage disease type IB patients |
| title_full_unstemmed | Empagliflozin as treatment in glycogen storage disease type IB patients |
| title_short | Empagliflozin as treatment in glycogen storage disease type IB patients |
| title_sort | empagliflozin as treatment in glycogen storage disease type ib patients |
| topic | Glycogen storage disease type Ib Empagliflozin Neutropenia Neutrophil dysfunction SGLT2 inhibitors 1,5-andhydroglucitol |
| url | http://www.sciencedirect.com/science/article/pii/S2214426925000412 |
| work_keys_str_mv | AT mariaarbelorodriguez empagliflozinastreatmentinglycogenstoragediseasetypeibpatients AT elenamarquezmesa empagliflozinastreatmentinglycogenstoragediseasetypeibpatients AT cristinalorenzogonzalez empagliflozinastreatmentinglycogenstoragediseasetypeibpatients AT marinagutierrezvilar empagliflozinastreatmentinglycogenstoragediseasetypeibpatients AT loredanaarhip empagliflozinastreatmentinglycogenstoragediseasetypeibpatients AT monicaruizpons empagliflozinastreatmentinglycogenstoragediseasetypeibpatients AT josepablosuarezllanos empagliflozinastreatmentinglycogenstoragediseasetypeibpatients |